PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients- A Markov Model
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1210
https://www.valueinhealthjournal.com/article/S1098-3015(11)02772-0/fulltext
Title :
PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients- A Markov Model
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02772-0&doi=10.1016/j.jval.2011.08.1210
First page :
A454
Section Title :
Cancer
Open access? :
No
Section Order :
1168